Wednesday, July 8, 2026

pharma · Coronary Artery Bypass Grafting · Hypertension Pulmonary Secondary · TENX

TENAX THERAPEUTICS

TENAX THERAPEUTICS is a pharma organization headquartered in Chapel Hill, USA. It trades on NYSE under ticker TENX. Primary therapeutic focus areas include Coronary Artery Bypass Grafting, Hypertension Pulmonary Secondar

Chapel Hill, USA HQ
19 Employees
Public company Type
TENX · NYSE Ticker
Company details
Status
Public
HQ
Chapel Hill, USA
Employees
19
Programs
7
Drugs
2
Patents
4
Clinical program

TNX-103

Phase 3 · small molecule · Pulmonary Hypertension Associated With HFpEF

TNX-103 for Pulmonary Hypertension Associated With HFpEF is a Phase 3 program (small_molecule) at TENAX THERAPEUTICS, INC. with 2 ClinicalTrials.gov record(s).

← All TENAX THERAPEUTICS, INC. projects Phase 3 small molecule active

Internal code TNX-103-08

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
TENAX THERAPEUTICS, INC.
Phase
Phase 3
Modality
small_molecule
Indication
Pulmonary Hypertension Associated With HFpEF
Status
active
Trials
2

Clinical trials